Purchasing a pipeline – perils, pitfalls, and priorities in asset acquisition

Checkpoint inhibitors. Genetic therapies. Biomarker therapies. To hear big pharma tell it, we are living in an age of medical wonders.

The problem? In some patients, they make a huge difference. In others, they don’t work at all.

From a bench-science standpoint, that’s fascinating. But if you’re a pharmaceutical executive thinking seriously about pipeline asset acquisition, translating large-molecule science into high-profit marketability is fraught with complexity.

In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.

Big pharma pipelines are not what they used to be

The majority of new drugs measure their success in increments.

Orphan drugs and tightly targeted MOAs offer the most exciting breakthroughs, but they offer them to smaller and smaller groups of patients. New cancer drugs are launched with great fanfare even when their pivotal studies suggest they offer a scant three months’ improvement over the competition. Small molecules are languishing. Biologics, once heralded as an arena of unbounded promise, are nearing the end of their patent lives, negotiating payments worth millions to keep biosimilars off the market.

Deallus Purchasing a Pipeline White Paper
DOWNLOAD WHITE PAPER

You may also be interested in…

  • AI in pharma

Can AI really help you understand what matters in your market?

The impact of AI across our industry will be profound. It’s already driving faster identification of novel drug targets and drug discovery, better patient identification, accelerated drug development, earlier diagnosis, and more personalized healthcare.

  • Brain Awareness Week

Brain Awareness Week

Brain Awareness Week is a global campaign held every March that aims to increase public support and excitement for brain science.

  • Rare Disease Day

Rare Diseases, Pharma’s Perennial Hitmaker

February 29th is the rarest day of the year, and this was in fact the reason why Rare Disease Day was established on this day 16 years ago by the European Organisation for Rare Diseases, commemorating the 25th anniversary of the U.S. Orphan Drug Act.

  • National Healthcare Security Administration (NHSA) protocols

National Healthcare Security Administration (NHSA) protocols

On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.